What is Myelofibrosis Market?
Myelofibrosis is a disease with high unmet medical need as the number of patients who are ineligible for or become resistant to existing therapy continues to increase. Myelofibrosis is an extraordinary sort of bone marrow disease and is identified with a gathering of blood malignancies known as myeloproliferative neoplasms. A basic blood test alongside a bone marrow biopsy can analyze myelofibrosis. Myelofibrosis is otherwise called ongoing myelosclerosis, agnogenic myeloid metaplasia, aleukemic megakaryocytic myelosis, idiopathic myelofibrosis, and leukoerythroblastosis. As per the report distributed by The Leukemia and Lymphoma Society (LLS) in the United States, myelofibrosis happens in about 1.5 out of each 100,000 individuals in the United States yearly. Patients over 50 years old are more inclined to the infection, however, it can happen at whatever stage in life. Myelofibrosis influences ladies and men with equivalent recurrence, however in kids, it is bound to influence young ladies more than young men. In spite of the fact that the treatment choices accessible for myelofibrosis are scant and practically all are interesting, the FDA endorsed (JAK inhibitor) drug-ruxolitinib structures a significant line of protection against myelofibrosis.
The market study is being classified by Type (Gene Mutation Analysis, Bone Marrow Biopsy, Imaging Tests and Blood Tests) and major geographies with country level break-up.
Novartis(Switzerland), Roche(Switzerland), Merck & Co. (United States), Eli Lilly(United States), Celgene(United States), Amgen(United States), Bristol-Myers Squibb(United States), Incyte Corporation(United States), Gilead Sciences(United States) and Sierra Oncology (Canada) are some of the key players profiled in the study.
The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Myelofibrosis market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Myelofibrosis market by Type, Application and Region.
On the basis of geography, the market of Myelofibrosis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Prevalence Of Myelofibrosis In Developing Economies Drives The Demand For Various Treatment Options For Myelofibrosis.
- Large Pool Of Patients Living With Myelofibrosis
- The rise in the Incidences Of Genetic Disorders, And Escalating Smoking Population
- High Costs Involved In Treatment
- Heavy Investments In Research And Development,
- Limited Awareness Of The Novel Therapies
Market Leaders and some development strategies
January 2020 Celgene United States-based biopharma company announced that it is set to acquire Impact Biomedicines and its drug fedratinib, which will be added to Celgene’s therapies for myelofibrosis.
In November 2019 Sierra Oncology Canada based company has launched its MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis. The randomized double-blind global Phase 3 trial is designed to confirm the efficacy of momelotinib on myelofibrosis symptoms, transfusion independence, and splenomegaly, as compared to danazol. The trial is targeting enrollment of 180 myelofibrosis patients who are symptomatic, anemic, and have been treated previously with a JAK inhibitor.
Key Target AudienceNew Entrants/Investors, Analysts and Strategic Business Planners, Myelofibrosis Providers, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase